Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Latinos and Cancer Information: Perspectives of Patients, Health Professionals and Telephone Cancer Information Specialists.

Journal of health disparities research and practice

Kaplan CP, Nápoles A, Davis S, Lopez M, Pasick RJ, Livaudais-Toman J, Pérez-Stable EJ.
PMID: 27642542
J Health Dispar Res Pract. 2016;9(2):154-167.

Semi-structured interviews were conducted with 16 Latino cancer patients diagnosed in California; 10 health professionals from the San Francisco Bay Area and Fresno, California; and 10 Cancer Information Services (CIS) information specialists from the regional offices handling calls from...

Cite
Kaplan CP, Nápoles A, Davis S, et al. Latinos and Cancer Information: Perspectives of Patients, Health Professionals and Telephone Cancer Information Specialists. J Health Dispar Res Pract. 2016;9(2):154-167
Kaplan, C. P., Nápoles, A., Davis, S., Lopez, M., Pasick, R. J., Livaudais-Toman, J., & Pérez-Stable, E. J. (2016). Latinos and Cancer Information: Perspectives of Patients, Health Professionals and Telephone Cancer Information Specialists. Journal of health disparities research and practice, 9(2), 154-167.
Kaplan, Celia P, et al. "Latinos and Cancer Information: Perspectives of Patients, Health Professionals and Telephone Cancer Information Specialists." Journal of health disparities research and practice vol. 9,2 (2016): 154-167.
Kaplan CP, Nápoles A, Davis S, Lopez M, Pasick RJ, Livaudais-Toman J, Pérez-Stable EJ. Latinos and Cancer Information: Perspectives of Patients, Health Professionals and Telephone Cancer Information Specialists. J Health Dispar Res Pract. 2016;9(2):154-167. PMID: 27642542; PMCID: PMC5023065.
Copy Download .nbib Format: NLM
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

NPJ breast cancer

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.
PMID: 28721379
NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute...

Cite
Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2:16017doi: 10.1038/npjbcancer.2016.17.
Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., Ward, K. C., Wiggins, C., Wu, X. C., Penberthy, L., & Shak, S. (2016). Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ breast cancer, 216017. https://doi.org/10.1038/npjbcancer.2016.17
Petkov, Valentina I, et al. "Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study." NPJ breast cancer vol. 2 (2016): 16017. doi: https://doi.org/10.1038/npjbcancer.2016.17
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016. PMID: 28721379; PMCID: PMC5515329.
Copy Download .nbib Format: NLM
Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort.

Oncotarget

Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD.
PMID: 29212164
Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07.

The underlying genetic cause of colorectal cancer (CRC) can be identified for 5-10% of all cases, while at least 20% of CRC cases are thought to be due to inherited genetic factors. Screening for highly penetrant mutations in genes...

Cite
Raskin L, Guo Y, Du L, et al. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017;8(55):93450-93463doi: 10.18632/oncotarget.18596.
Raskin, L., Guo, Y., Du, L., Clendenning, M., Rosty, C., Lindor, N. M., Gruber, S. B., & Buchanan, D. D. (2017). Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget, 8(55), 93450-93463. https://doi.org/10.18632/oncotarget.18596
Raskin, Leon, et al. "Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort." Oncotarget vol. 8,55 (2017): 93450-93463. doi: https://doi.org/10.18632/oncotarget.18596
Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07. PMID: 29212164; PMCID: PMC5706810.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017).

Cancer investigation

Penn DC, Baker M, Geiger AM, Harlan LC.
PMID: 30136865
Cancer Invest. 2018;36(6):319-329. doi: 10.1080/07357907.2018.1474894. Epub 2018 Aug 23.

BACKGROUND: Cancer health services research is a primary tool for analyzing the association between various factors, cancer health care delivery, and the resultant outcomes. To address disparities strategies must be developed to target factors that are related to differences...

Cite
Penn DC, Baker M, Geiger AM, et al. Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017). Cancer Invest. 2018;36(6):319-329doi: 10.1080/07357907.2018.1474894.
Penn, D. C., Baker, M., Geiger, A. M., & Harlan, L. C. (2018). Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017). Cancer investigation, 36(6), 319-329. https://doi.org/10.1080/07357907.2018.1474894
Penn, Dolly C, et al. "Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017)." Cancer investigation vol. 36,6 (2018): 319-329. doi: https://doi.org/10.1080/07357907.2018.1474894
Penn DC, Baker M, Geiger AM, Harlan LC. Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017). Cancer Invest. 2018;36(6):319-329. doi: 10.1080/07357907.2018.1474894. Epub 2018 Aug 23. PMID: 30136865; PMCID: PMC6295665.
Copy Download .nbib Format: NLM
Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer.

JCO precision oncology

Katz SJ, Ward KC, Hamilton AS, Abrahamse P, Hawley ST, Kurian AW.
PMID: 30656245
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00225. Epub 2018 Dec 19.

BACKGROUND: There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.METHODS: Patients with breast cancer diagnosed from 2013 to...

Cite
Katz SJ, Ward KC, Hamilton AS, et al. Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. JCO Precis Oncol. 2018;2018doi: 10.1200/PO.18.00225.
Katz, S. J., Ward, K. C., Hamilton, A. S., Abrahamse, P., Hawley, S. T., & Kurian, A. W. (2018). Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. JCO precision oncology, 2018. https://doi.org/10.1200/PO.18.00225
Katz, Steven J, et al. "Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer." JCO precision oncology vol. 2018 (2018). doi: https://doi.org/10.1200/PO.18.00225
Katz SJ, Ward KC, Hamilton AS, Abrahamse P, Hawley ST, Kurian AW. Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00225. Epub 2018 Dec 19. PMID: 30656245; PMCID: PMC6333469.
Copy Download .nbib Format: NLM
Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Barbetta A, Goldbeck C, Lim A, Martin SP, Kahn JA, Sheikh MR, Emamaullee J.
PMID: 34294525
HPB (Oxford). 2021 Jul 06; doi: 10.1016/j.hpb.2021.06.420. Epub 2021 Jul 06.

BACKGROUND: Sickle cell disease (SCD) is a rare hemoglobinopathy which can result in chronic liver disease and cirrhosis. Patients with SCD have an increased risk of hematologic malignancy, but the prevalence of hepatocellular carcinoma (HCC) in this population is...

Cite
Barbetta A, Goldbeck C, Lim A, et al. Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S. HPB (Oxford). 2021;doi: 10.1016/j.hpb.2021.06.420.
Barbetta, A., Goldbeck, C., Lim, A., Martin, S. P., Kahn, J. A., Sheikh, M. R., & Emamaullee, J. (2021). Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S. HPB : the official journal of the International Hepato Pancreato Biliary Association, . https://doi.org/10.1016/j.hpb.2021.06.420
Barbetta, Arianna, et al. "Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. (2021). doi: https://doi.org/10.1016/j.hpb.2021.06.420
Barbetta A, Goldbeck C, Lim A, Martin SP, Kahn JA, Sheikh MR, Emamaullee J. Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S. HPB (Oxford). 2021 Jul 06; doi: 10.1016/j.hpb.2021.06.420. Epub 2021 Jul 06. PMID: 34294525; PMCID: PMC8733051.
Copy Download .nbib Format: NLM
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.

Urologic oncology

Liu Y, Hall IJ, Filson C, Howard DH.
PMID: 33308973
Urol Oncol. 2021 Jul;39(7):432.e1-432.e10. doi: 10.1016/j.urolonc.2020.11.024. Epub 2020 Dec 09.

BACKGROUND: The treatment for men diagnosed with localized prostate cancer has changed over time given the increased attention to the harms associated with over-diagnosis and the development of protocols for active surveillance.METHODS: We examined trends in the treatment of...

Cite
Liu Y, Hall IJ, Filson C, et al. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urol Oncol. 2020;39(7):432.e1-432.e10doi: 10.1016/j.urolonc.2020.11.024.
Liu, Y., Hall, I. J., Filson, C., & Howard, D. H. (2021). Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urologic oncology, 39(7), 432.e1-432.e10. https://doi.org/10.1016/j.urolonc.2020.11.024
Liu, Yu, et al. "Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer." Urologic oncology vol. 39,7 (2021): 432.e1-432.e10. doi: https://doi.org/10.1016/j.urolonc.2020.11.024
Liu Y, Hall IJ, Filson C, Howard DH. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urol Oncol. 2021 Jul;39(7):432.e1-432.e10. doi: 10.1016/j.urolonc.2020.11.024. Epub 2020 Dec 09. PMID: 33308973; PMCID: PMC8374746.
Copy Download .nbib Format: NLM
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 34678077
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.

PURPOSE: A previous cancer diagnosis is a negative consideration in evaluating patients for possible solid organ transplantation. Statistical models may improve selection of patients with cancer evaluated for transplantation.METHODS: We fitted statistical cure models for patients with cancer in...

Cite
Engels EA, Haber G, Hart A, et al. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021;39(36):4039-4048doi: 10.1200/JCO.21.01195.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4039-4048. https://doi.org/10.1200/JCO.21.01195
Engels, Eric A, et al. "Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4039-4048. doi: https://doi.org/10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22. PMID: 34678077; PMCID: PMC8677988.
Copy Download .nbib Format: NLM
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 34678077
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.

PURPOSE: A previous cancer diagnosis is a negative consideration in evaluating patients for possible solid organ transplantation. Statistical models may improve selection of patients with cancer evaluated for transplantation.METHODS: We fitted statistical cure models for patients with cancer in...

Cite
Engels EA, Haber G, Hart A, et al. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021;39(36):4039-4048doi: 10.1200/JCO.21.01195.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4039-4048. https://doi.org/10.1200/JCO.21.01195
Engels, Eric A, et al. "Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4039-4048. doi: https://doi.org/10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22. PMID: 34678077; PMCID: PMC8677988.
Copy Download .nbib Format: NLM
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM.
PMID: 34678077
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.

PURPOSE: A previous cancer diagnosis is a negative consideration in evaluating patients for possible solid organ transplantation. Statistical models may improve selection of patients with cancer evaluated for transplantation.METHODS: We fitted statistical cure models for patients with cancer in...

Cite
Engels EA, Haber G, Hart A, et al. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021;39(36):4039-4048doi: 10.1200/JCO.21.01195.
Engels, E. A., Haber, G., Hart, A., Lynch, C. F., Li, J., Pawlish, K. S., Qiao, B., Yu, K. J., & Pfeiffer, R. M. (2021). Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4039-4048. https://doi.org/10.1200/JCO.21.01195
Engels, Eric A, et al. "Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4039-4048. doi: https://doi.org/10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, Qiao B, Yu KJ, Pfeiffer RM. Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis. J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22. PMID: 34678077; PMCID: PMC8677988.
Copy Download .nbib Format: NLM
Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities.

JNCI cancer spectrum

Sheth Bhutada J, Hwang A, Liu L, Deapen D, Freyer DR.
PMID: 34250441
JNCI Cancer Spectr. 2021 Apr 27;5(3):pkab039. doi: 10.1093/jncics/pkab039. eCollection 2021 Jun.

BACKGROUND: For adolescents and young adults (AYAs, aged 15-39 years) with cancer, metastatic disease at diagnosis is the strongest predictor of mortality, but its associations with age and sociodemographic factors are largely unexplored.METHODS: Using Surveillance, Epidemiology, and End Results...

Cite
Sheth Bhutada J, Hwang A, Liu L, et al. Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities. JNCI Cancer Spectr. 2021;5(3):pkab039doi: 10.1093/jncics/pkab039.
Sheth Bhutada, J., Hwang, A., Liu, L., Deapen, D., & Freyer, D. R. (2021). Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities. JNCI cancer spectrum, 5(3), pkab039. https://doi.org/10.1093/jncics/pkab039
Sheth Bhutada, Jessica, et al. "Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities." JNCI cancer spectrum vol. 5,3 (2021): pkab039. doi: https://doi.org/10.1093/jncics/pkab039
Sheth Bhutada J, Hwang A, Liu L, Deapen D, Freyer DR. Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities. JNCI Cancer Spectr. 2021 Apr 27;5(3):pkab039. doi: 10.1093/jncics/pkab039. eCollection 2021 Jun. PMID: 34250441; PMCID: PMC8266435.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries